John Oyler Sells 101,000 Shares of Beigene, Ltd. (NASDAQ:ONC) Stock

Beigene, Ltd. (NASDAQ:ONCGet Free Report) CEO John Oyler sold 101,000 shares of Beigene stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $244.30, for a total value of $24,674,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Beigene Trading Up 1.9 %

Beigene stock traded up $4.90 during midday trading on Wednesday, reaching $262.21. The company had a trading volume of 567,803 shares, compared to its average volume of 455,367. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. Beigene, Ltd. has a 12-month low of $126.97 and a 12-month high of $287.88. The firm has a market capitalization of $25.66 billion, a PE ratio of -31.82, a P/E/G ratio of 7.73 and a beta of 0.63.

Beigene (NASDAQ:ONCGet Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). The firm had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. On average, sell-side analysts predict that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ONC shares. Bank of America upgraded Beigene from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $207.00 to $320.00 in a research report on Monday. Macquarie boosted their price target on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a report on Friday, February 28th.

Get Our Latest Research Report on Beigene

About Beigene

(Get Free Report)

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Featured Stories

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.